10 may sbrt
TRANSCRIPT
![Page 1: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/1.jpg)
Stereotactic body radiation therapy
(SBRT)
Dr Sadia Sadiq
PGR 2,INMOL
![Page 2: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/2.jpg)
Historical Perspective
We should recognize and acknowledge that Stereotactic Body Radiation Therapy (SBRT) is an extension or evolution of Stereotactic Radiosurgery (SRS)
![Page 3: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/3.jpg)
Why ?
If we acknowledge this evolution, we should also provide EXTRA-ORDINARY
CARE for SBRT as demanded in Stereotactic Radiosurgery (SRS)
![Page 4: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/4.jpg)
Questions: Why is EXTRA-ORDINARYCARE necessary?
Why is EXTRA-ORDINARYCARE needed ?
![Page 5: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/5.jpg)
Stereotactic body radiation therapy (SBRT)Management and delivery of image -guided high-dose radiation therapy with tumor-ablative intent within a course of treatment that does not exceed 5 fractions American Society of Therapeutic Radiology and Oncology (ASTRO)
Also called SART
![Page 6: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/6.jpg)
Tumors include lung, liver, spine, pancreas, kidney, and prostate.
Prospective trials have demonstrated efficacy and acceptable acute and subacute toxicities
Late toxicity requires further careful assessment
![Page 7: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/7.jpg)
Radiation: Fractionation
Standard fractionation: 1.8-2.0 Gy a day, 5 days a week for 25-30 treatments
Conventional hypofractionation:3-5 Gy a day, 5 days a week for 10-15 treatments
Stereotactic radiotherapy:15-25 Gy a day, 1-3 days a week for 1-5 treatments
![Page 8: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/8.jpg)
Rationale of SBRT
Conceptual theories of cancer growth and numerous lines of evidence behind use of SBRT for metastatic lesions are
(a) The Empiric Or Phenomenological,
(B) The Patterns-of-failure Concept,
(C) The Theory Of Oligo metastases,
(D) A Lethal Burden Variation Of The Norton-simon Hypothesis, Or
(E) Immunological Enhancement.
![Page 9: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/9.jpg)
Methods Of Cell Kill in SBRT
DNA damage
Anti Angiogenesis
Endothelial cell Apoptoses
![Page 10: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/10.jpg)
1. Qualified personnel: a. Board-certified radiation oncologist b. Qualified medical physicist c. Licensed radiation therapist d. Other support staff as
indicated (dosimetrists, oncology
2. Ongoing machine quality assurance program; 3. Documentation in accordance with the ACR Practice Guideline
for Communication: Radiation Oncology;
4. Quality control of treatment accessories; 5. Quality control of planning and treatment images; 6. Quality control of treatment planning system; 7. Simulation and treatment systems based on actual measurement of organ motion and setup uncertainty.
![Page 11: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/11.jpg)
SBRT PHYSICS AND TECHNOLOGY
1. CT simulation: Assess tumor motion
2. Immobilization: Minimize motion, breathing effects
3. Planning: Small field dosimetry considerations
4. Repositioning: High precision patient set-up: Fiducial systems, IR/LED Active and Passive markers, US, Video
5. Relocalization: Identify tumor location in the treatment field: * MV/ KV Xray, Implanted markers and/or set-up fiducials* Motion tracking and gating systems* Real-time tumor tracking systems with implanted markers
6. Treatment delivery techniques Adapted conventional systems Specialized SRT: Novalis, Cyberknife, Trilogy
![Page 12: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/12.jpg)
4D CT Simulator
A technique that allow anevaluation of themotion of the targetFigure: Christopher Willey, MD, PhD
![Page 13: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/13.jpg)
4D CT Simulator
The trace of the target motionallow the creation of ainternal target volume(ITV) for treatmentplanning
![Page 14: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/14.jpg)
Stereo ImagingTechnology:
To localized the target on images On-Board Imager onLinac In-Room Localizer
![Page 15: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/15.jpg)
Breathing-related motion control devices and systems fall into three general categories:
(a) dampening,
(b) gating, and
(c) tracking or “chasing.”
![Page 16: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/16.jpg)
Respiratory dampening techniques Include systems of abdominal compression
intended to diminish one of the largest contributors to breathing-related motion, namely diaphragmatic excertion.
![Page 17: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/17.jpg)
ABC:
Also included in this category are the systems employing breath-holding maneuvers to stabilize the tumor in a reproducible stage of the respiratory cycle (e.g., deep inspiration).
![Page 18: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/18.jpg)
Gating systems for SBRT
It follow the respiratory cycle using a surrogate indicator for respiratory motion, for example, chest wall motion, and employ an electronic beam activation trigger allowing irradiation to occur only during a specified range of expected tumor locations.
![Page 19: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/19.jpg)
![Page 20: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/20.jpg)
Clinical Experience withStereotactic Body RadiationTherapy in Selected Sites
1)Lung2)Liver3)Spine4)Prostate5)Pancreas
![Page 21: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/21.jpg)
SBRT:LUNG
Indications:
Stage I NSCLC
Pulmonary metastases
![Page 22: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/22.jpg)
![Page 23: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/23.jpg)
One important observation from the Indiana University studies was that although the treatment was generally well tolerated,
tumor location near large airways in the vicinity of the pulmonary hilum (called the zone of the proximal bronchial tree) was associated with a markedly higher risk of toxicity.
![Page 24: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/24.jpg)
RTOG 0236:
•59 patients• Median age 72• All pts inoperable•T1 – 80%; T2- 20%•Dose: 60Gy in 3 fxs (BED 180)
Median FU 3 yrs:•Local control = 97.6%•Distant mets = 22.1%
•Overall survival @3yrs = 55.8%•Median survival = 48 months
![Page 25: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/25.jpg)
Pulmonary metastases
![Page 26: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/26.jpg)
![Page 27: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/27.jpg)
![Page 28: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/28.jpg)
SBRT: LIVER
Underlying severe liver disease often renders patients medically inoperable
Other nonsurgical therapies have generally achieved at best rather modest success in that setting.
![Page 29: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/29.jpg)
Challenges in Targeting Liver TumorsLimited visualization of the targetLiver deformation with respiration Changes in GI organ luminal filling
Critical structures (stomach) may change in shape and position between planning and treatment
Interfraction target displacement with respect to bony anatomy
![Page 30: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/30.jpg)
Abdominal Compression
Abdominal belt with inflatable bladder
Inflation: 15-40 mmHg
![Page 31: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/31.jpg)
First Liver SBRT Experience 50 patients treated to 75 lesions with SBRT for primary and metastatic liver tumors
15 to 45 Gy, 1-5 fractions Mean follow-up of 12 months 30% of tumors demonstrated growth arrest, 40% were reduced in size, and 32% disappeared by imaging studies
4 local failures (5.3%) Mean survival time was 13.4 months
Blomgren, et. al., J Radiosurgery, 1998
![Page 32: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/32.jpg)
![Page 33: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/33.jpg)
![Page 34: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/34.jpg)
SBRT:SPINE
SBRT is an emerging technology used for the treatment of spinal tumors.
Effective dose escalation For patients who are not candidates for conventional radiotherapy
To improve the quality of life for patients who may be spared a prolonged treatment course.
Acute Radiation toxicity is reduced.
![Page 35: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/35.jpg)
Indications for Spinal SBRT
Pain control in vertebral metastases
Malignant Epidural Spinal Cord compression
Benign Spinal Cord Tumors
![Page 36: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/36.jpg)
Dose volume constraints
In a Randomized trail of 260 patients investigators have not observed a single case of Myelopathy at 1 year with dose of 8Gy *1fr.
Partial volume tolerance of the human spinal cord to Radiosurgery was analyzed in 177 patients with 230 metastatic lesions.
The authors concluded that an acceptable estimate of partial cord tolerance is 10 Gy to the 10% volume.
1.Rades D, Stalpers LJ, Veninga T et al. J Clin Oncol 23:3366–3375
2.Ryu S, Jin JY, Jin R et al 2007Cancer 109:628–636
![Page 37: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/37.jpg)
The a/b ratio of Prostrate Cancer is lower than for most other tumors. Values between 1.2 and 3 Gy are suggested.
It is lower than surrounding normal tissues like rectum (a/b of 4 Gy for late rectal sequelae).
It is hypothesized that hypofractionation if accurately delivered increases the tumor control by sparing surrounding late responding normal tissues.
SBRT:PROSTRATE
![Page 38: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/38.jpg)
Indications
Primary treatment for organ confined low risk prostrate cancer
Dose escalation for intermediate and high risk prostrate cancer
![Page 39: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/39.jpg)
prostate
![Page 40: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/40.jpg)
SBRT: PANCREAS
Stereotactic body radiation therapy (SBRT) In Pancreas is indicated for
1.Boderline resectable tumors to improve resectability in Neo Adjuvuvant setting.
2.In Unresectable due to their lower life expectancy to reduce 5 -6 weeks treatment to less than 5 days
3.In resectecd Ca Pancreas with positive margins.
![Page 41: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/41.jpg)
Challenges of SBRT in Pancreas
The head of the pancreas, where majority of tumors reside, is in close proximity to the C-loop of the duodenum
Delivery of conventionally fractionated radiation (1.8–2 Gy/day) to more than 50 Gy results in damage to the small bowel such as ulcerations, stenosis, bleeding, and perforation.
The pancreas move with respiration, as well as with peristalsis that is not easily predictable.
![Page 42: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/42.jpg)
![Page 43: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/43.jpg)
![Page 44: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/44.jpg)
SIDE EFFECTS
Radiobiology: Tumor vs. Normal Tissue
Normal Tissue ToxicityLung: pneumonitis and fibrosisPancreas: duodenum and stomachSpine lesions: cordProstate: rectum and bladderLiver: normal liver (radiation induced liver disease-RILD)
![Page 45: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/45.jpg)
The dose constraints of SBRT
![Page 46: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/46.jpg)
![Page 47: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/47.jpg)
![Page 48: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/48.jpg)
![Page 49: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/49.jpg)
Stereotactic Body Radiation Therapy:
The Report of AAPM Task Group 101
![Page 50: 10 may sbrt](https://reader033.vdocuments.us/reader033/viewer/2022061609/55cadbcbbb61eb3c2b8b47f0/html5/thumbnails/50.jpg)
The SBRT:Ultimate “Targeted Therapy”